These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Wimo A; Karlsson G; Nordberg A; Winblad B Alzheimer Dis Assoc Disord; 1997 Dec; 11(4):191-200. PubMed ID: 9437436 [TBL] [Abstract][Full Text] [Related]
36. [Long-term treatment of Alzheimer's disease: followup of a cohort of 255 patients treated with lacrine for four years]. Michel BF; Estadieu MC; Gueriot C; Berthezène P; Allain H; Bongrand MC; Bonnefoy B; Bourrin JC; Chaix L; Graa K; Lejeune A; Messana M; Pras P; Ribiere J; Rihet P; Timon-David P; Tintignac A; Vincent S; Verdier JM; Gastaut JL Rev Neurol (Paris); 2001 Nov; 157(11 Pt 1):1365-75. PubMed ID: 11924005 [TBL] [Abstract][Full Text] [Related]
37. Alzheimer's disease: a treatment in sight? Lovestone S; Howard R J Neurol Neurosurg Psychiatry; 1995 Dec; 59(6):566-7. PubMed ID: 7500092 [No Abstract] [Full Text] [Related]
38. Meta-analysis of tacrine for Alzheimer disease: the influence of industry sponsors. Koepp R; Miles SH JAMA; 1999 Jun 23-30; 281(24):2287-8. PubMed ID: 10386551 [No Abstract] [Full Text] [Related]
39. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease. Prescrire Int; 2001 Dec; 10(56):180-1. PubMed ID: 11824442 [TBL] [Abstract][Full Text] [Related]
40. Enhancing the tolerability of tacrine with propantheline. Faber RA; Negro PJ Am J Psychiatry; 1999 Jan; 156(1):156. PubMed ID: 9892315 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]